1357259-50-7 Usage
Class
Pyridine derivatives
Usage
Intermediate in the synthesis of pharmaceuticals and agrochemicals
Potential Application
Treatment of neurological disorders
Role
Building block in the development of new drug candidates
Chemical Structure
Contains an amino group and a bromine atom
Functional Groups
Amino and bromine atoms contribute to reactivity and biological activity
Field of Application
Medicinal chemistry and drug discovery
Solubility
Soluble in water and most organic solvents
Stability
Stable under normal temperature and pressure conditions
Purity
Typically synthesized with high purity for use in pharmaceutical applications
Safety
Handle with care, as it may have potential hazards depending on its concentration and exposure
Storage
Store in a cool, dry place, away from direct sunlight and moisture
Regulatory Status
May be subject to specific regulations depending on the intended use and jurisdiction
Check Digit Verification of cas no
The CAS Registry Mumber 1357259-50-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,7,2,5 and 9 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1357259-50:
(9*1)+(8*3)+(7*5)+(6*7)+(5*2)+(4*5)+(3*9)+(2*5)+(1*0)=177
177 % 10 = 7
So 1357259-50-7 is a valid CAS Registry Number.
1357259-50-7Relevant articles and documents
Concise SAR Exploration Based on the "head-to-Tail" Approach: Discovery of PI4KIIIα Inhibitors Bearing Diverse Scaffolds
Noji, Satoru,Seki, Noriyoshi,Maeba, Takaki,Sakai, Takayuki,Watanabe, Eiichi,Maeda, Katsuya,Fukushima, Kyoko,Noguchi, Toru,Ogawa, Kazuya,Toyonaga, Yukiyo,Negoro, Tamotsu,Kawasaki, Hisashi,Shiozaki, Makoto
supporting information, p. 919 - 923 (2016/10/22)
In typical kinase inhibitor programs, a hinge binder showing best potency with preferential specificity is initially selected, followed by fine-tuning of the accompanying substituents on its core module. A shortcoming of this approach is that the exclusiv
HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS
-
Page/Page column 77, (2012/02/13)
Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R' have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors,in HCV therapy.
